Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PITX2

PITX2

Basics

Aliases:
This biomarker is also known as:
  • RGS,
  • paired-like homeodomain 2,
  • IGDS,
  • RS,
  • IRID2,
  • IGDS2,
  • IDG2,
  • RIEG bicoid-related homeobox transcription factor,
  • RIEG,
  • rieg bicoid-related homeobox transcription factor 1,
  • pituitary homeo box 2,
  • PTX2,
  • all1-responsive gene 1,
  • Homeobox protein PITX2,
  • Brx1,
  • Paired-like homeodomain transcription factor 2,
  • pituitary homeobox 2,
  • solurshin,
  • Solurshin,
  • RIEG1,
  • Otlx2,
  • IHG2,
  • ARP1,
  • ALL1-responsive protein ARP1,

View in BioMuta

Description…

The PITX2 protein is a member of the RIEG/PITX paired homeobox family, in the bicoid class of homeodomain proteins. PITX2 acts as a transcription factor, controls cell proliferation in a tissue-specific manner and is involved in morphogenesis. During embryonic development, PITX2 exerts a role in the expansion of muscle progenitors. Several alternatively spliced transcripts have been identified encoding different isoforms.

Attributes

QA State: Under Review
Type: Gene
Short Name:
HGNC Name: PITX2

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.